Galapagos and Cellzome are collaborating in kinase drug discovery. Under the terms of the agreement, Galapagos’ service division, BioFocus DPI, will give Cellzome access to its SoftFocus® kinase libraries and will provide biological screening and chemistry expertise to find inhibitors of Cellzome’ skinase targets. BioFocus will receive an upfront payment for the library access as well as research fees.

The companies will use Cellzome’s Kinobeads technology to screen the BioFocus DPI libraries for the identification of inhibitors against key inflammatory kinases in their physiological context.

Previous articleBiomarker Blood Test May Detect Lung Cancer at Earliest Stage
Next articleGilead Buys Corus Pharma for $365 million